title: The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
authors.affiliation: Division of Cardiology and Colorado Prevention Center Clinical Research, Department of Medicine, University of Colorado School of Medicine, Aurora, USA.
authors.forename: William R
authors.initials: WR
authors.lastname: Hiatt
authors.forename: Sanjay
authors.initials: S
authors.lastname: Kaul
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Smith
mesh_terms: D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced; D000077154:Rosiglitazone; D056737:Safety-Based Drug Withdrawals; D045162:Thiazolidinediones / Q000009:adverse effects*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone